Sourcing & Management of Health Products

Withdrawal of the Quality Assurance Information Notice 2018-02 Regarding Dolutegravir

06 December 2019

The Quality Assurance Information Notice 2018-02 providing recommendations regarding the safety communication on the use of Dolutegravir (DTG) in women of childbearing age is withdrawn.

This is to reflect the WHO update of recommendations on first and second line antiretroviral regimens published in July 2019.